Understanding the Physiology of FGF21

Annual Review of Physiology

Volumn 78, Issue , 2016, Pages 223-241

  Fisher, Ffolliott Martin ^a   Maratos Flier, Eleftheria ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Adipose; Diet; Fat; Liver; Obesity; klotho

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; FATTY ACID; FIBROBLAST GROWTH FACTOR;

ADIPOSE TISSUE; BIOCHEMISTRY; CENTRAL NERVOUS SYSTEM; DRUG MECHANISM; GENETICS; HUMAN; LIVER; METABOLIC REGULATION; NONHUMAN; PANCREAS; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DIABETES MELLITUS; FATTY LIVER; HOMEOSTASIS; LIPID METABOLISM; METABOLIC DISORDER; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS; FATTY ACIDS; FATTY LIVER; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; LIPID METABOLISM; METABOLIC DISEASES;

EID: 84958620673     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021115-105339     Document Type: Review

References (114)

1. Maratos-Flier E. 2016. Appetite regulation and thermogenesis. In Endocrinology: Adult and Pediatric, Vol. 1, ed. J Jamson, pp. 457-78. Philadelphia, PA: Elsevier/Saunders
2. Oulion S, Bertrand S, Escriva H. 2012. Evolution of the FGF gene family. Int. J. Evol. Biol. 2012:298147
3. Itoh N, Ornitz DM. 2008. Functional evolutionary history of the mouse Fgf gene family. Dev. Dyn. 237:18-27
4. Tanaka T, Ngwa JS, van Rooij FJ, Zillikens MC, Wojczynski MK, et al. 2013. Genome-wide metaanalysis of observational studies shows common genetic variants associated with macronutrient intake. Am. J. Clin. Nutr. 97:1395-402
5. Chu AY, Workalemahu T, Paynter NP, Rose LM, Giulianini F, et al. 2013. Novel locus including FGF21 is associated with dietary macronutrient intake. Hum. Mol. Genet. 22:1895-902
6. Nishimura T, Nakatake Y, Konishi M, Itoh N. 2000. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492:203-6
7. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. 2005. FGF-21 as a novel metabolic regulator. J. Clin. Investig. 115:1627-35
8. Coskun T, Bina HA, Schneider MA,Dunbar JD,Hu CC, et al. 2008. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-27
9. Xu J, Stanislaus S,Chinookoswong N, Lau YY, HagerT, et al. 2009. Acute glucose-lowering and insulinsensitizing action of FGF21 in insulin resistant mouse models-association with liver and adipose tissue effects. Am. J. Physiol. Endocrinol. Metab. 297:E1105-14
10. Kharitonenkov A,Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. 2007. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-81
11. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. 2007. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5:426-37
12. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, et al. 2007. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 5:415-25
13. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. 2009. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150:4931-40
14. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, et al. 2008. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J. Cell Physiol. 215:1-7
15. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, et al. 2007. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282:26687-95
16. Yie J,WangW, Deng L, Tam LT, Stevens J, et al. 2012. Understanding the physical interactions in the FGF21/FGFR/ β-Klotho complex: structural requirements and implications in FGF21 signaling. Chem. Biol. Drug Des. 79:398-410
17. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, et al. 2009. Different roles of N-and C-termini in the functional activity of FGF21. J. Cell. Physiol. 219:227-34
18. Yie J, Hecht R, Patel J, Stevens J,WangW, et al. 2009. FGF21 N-and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583:19-24
19. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, et al. 2012. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 16:387-93
20. Adams AC, Cheng CC, Coskun T, Kharitonenkov A. 2012. FGF21 requires βklotho to act in vivo. PLOS ONE 7:e49977
21. Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, et al. 2011. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology 152:2996-3004
22. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. 2009. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-59
23. Johnson CL, Weston JY, Chadi SA, Fazio EN, Huff MW, et al. 2009. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 137:1795-804
24. WenteW, Efanov AM, BrennerM, Kharitonenkov A, Koster A, et al. 2006. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55:2470-78
25. Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, et al. 2013. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 19:1147-52
26. Liang Q, Zhong L, Zhang J,Wang Y, Bornstein SR, et al. 2014. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 63:4064-75
27. Kaess BM, Barnes TA, Stark K, Charchar FJ,Waterworth D, et al. 2010. FGF21 signalling pathway and metabolic traits-genetic association analysis. Eur. J. Hum. Genet. 18:1344-48
28. Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, et al. 2011. A Klotho β variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 140:1934-42
29. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, et al. 2008. βKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22:1006-14
30. Ming AY, Yoo E, Vorontsov EN, Altamentova SM, Kilkenny DM, Rocheleau JV. 2012. Dynamics and distribution of Klotho β (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex. J. Biol. Chem. 287:19997-20006
31. Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, et al. 2012. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2:31-37
32. Lin BC, Wang M, Blackmore C, Desnoyers LR. 2007. Liver-specific activities of FGF19 require Klotho β. J. Biol. Chem. 282:27277-84
33. PohW,WongW,Ong H, Aung MO, Lim SG, et al. 2012. Klotho-βoverexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol. Cancer 11:14
34. HagelM,Miduturu C, SheetsM, RubinN,WengW, et al. 2015. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 5:424-37
35. Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, et al. 2011. Amelioration of type 2 diabetes by antibodymediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 3:113ra26
36. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, et al. 2007. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARγsignaling. J. Cell. Physiol. 210:1-6
37. Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. 2011. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J. Biol. Chem. 286:34533-41
38. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, et al. 2010. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456-63
39. Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, et al. 2008. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Mol. Pharmacol. 74:403-12
40. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, et al. 2010. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781-89
41. Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. 2012. TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153:4238-45
42. So WY, Cheng Q, Chen L, Evans-Molina C, Xu A, et al. 2013. High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γsignaling. Diabetes 62:3751-59
43. Hale C, ChenMM,Stanislaus S,Chinookoswong N, HagerT, et al. 2012. Lack of overt FGF21resistance in two mouse models of obesity and insulin resistance. Endocrinology 153:69-80
44. Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, et al. 2011. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 54:3093-100
45. Adams AC, Coskun T, Cheng CC, O'Farrell LS, Dubois SL, Kharitonenkov A. 2013. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol. Metab. 2:205-14
46. Gallego-Escuredo JM, Gomez-Ambrosi J, Catalan V, Domingo P, Giralt M, et al. 2015. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptormachinery for endocrine FGFs in obese patients. Int. J. Obes. 39:121-29
47. Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, et al. 2007. PPARα is a key regulator of hepatic FGF21. Biochem. Biophys. Res. Commun. 360:437-40
48. De Sousa-Coelho AL, Relat J, Hondares E, Perez-Marti A, Ribas F, et al. 2013. FGF21 mediates the lipid metabolism response to amino acid starvation. J. Lipid Res. 54:1786-97
49. Pissios P, Hong S, Kennedy AR, Prasad D, Liu FF, Maratos-Flier E. 2013. Methionine and choline regulate the metabolic phenotype of a ketogenic diet. Mol. Metab. 2:306-13
50. Lees EK, Krol E, Grant L, Shearer K, Wyse C, et al. 2014. Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. Aging Cell 13:817-27
51. De Sousa-Coelho AL, Marrero PF,HaroD. 2012. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem. J. 443:165-71
52. Shimizu N, Maruyama T, Yoshikawa N, Matsumiya R, Ma Y, et al. 2015. A muscle-liver-fat signalling axis is essential for central control of adaptive adipose remodelling. Nat. Commun. 6:6693
53. Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, et al. 2014. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation inmice on methionine and choline-deficient diets. Gastroenterology 147:1073-83.e6
54. Tanaka N, Takahashi S, Zhang Y, Krausz KW, Smith PB, et al. 2015. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine-and choline-deficient diet. Biochim. Biophys. Acta 1852:1242-52
55. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, et al. 2014. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63:4057-63
56. Berglund ED, Li CY, BinaHA, Lynes SE, MichaelMD, et al. 2009. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150:4084-93
57. Lin X, Li G, He X,Ma X, Zhang K, et al. 2014. FGF21 inhibits apolipoprotein(a) expression in HepG2 cells via the FGFR1-ERK1/2-Elk-1 pathway. Mol. Cell. Biochem. 393:33-42
58. Li Y, Wong K, Giles A, Jiang J, Lee JW, et al. 2014. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 146:539-49.e7
59. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, et al. 2009. FGF21 induces PGC-1αand regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. PNAS 106:10853-58
60. Uebanso T, Taketani Y, Yamamoto H, Amo K, Ominami H, et al. 2011. Paradoxical regulation of human FGF21 by both fasting and feeding signals: Is FGF21 a nutritional adaptation factor? PLOS ONE 6:e22976
61. Iizuka K, Takeda J, Horikawa Y. 2009. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett. 583:2882-86
62. Sanchez J, Palou A, Pico C. 2009. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. Endocrinology 150:5341-50
63. Camporez JP, Jornayvaz FR, Petersen MC, Pesta D, Guigni BA, et al. 2013. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154:3099-109
64. Li X, Ge H, Weiszmann J, Hecht R, Li YS, et al. 2009. Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Lett. 583:3230-34
65. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Ryden M. 2008. FGF21 attenuates lipolysis in human adipocytes-A possible link to improved insulin sensitivity. FEBS Lett. 582:1725-30
66. Hotta Y, Nakamura H, KonishiM,Murata Y,TakagiH, et al. 2009. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 150:4625-33
67. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. 2010. Hepatic FGF21 expression is induced at birth via PPARαin response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab. 11:206-12
68. Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, et al. 2011. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J. Biol. Chem. 286:12983-90
69. Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. 2011. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol. Med. 17:736-40
70. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, et al. 2012. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 26:271-81
71. Lee P, Brychta RJ, Linderman J, Smith S, Chen KY, Celi FS. 2013. Mild cold exposure modulates fibroblast growth factor 21 (FGF21) diurnal rhythm in humans: relationship between FGF21 levels, lipolysis, and cold-induced thermogenesis. J. Clin. Endocrinol. Metab. 98:E98-102
72. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. 2010. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1αpathway. PNAS 107:12553-58
73. Emanuelli B, Vienberg SG, Smyth G, Cheng C, Stanford KI, et al. 2014. Interplay between FGF21 and insulin action in the liver regulates metabolism. J. Clin. Investig. 124:515-27
74. Samms RJ, Smith DP,Cheng CC, Antonellis PP, Perfield JW2nd, et al. 2015. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep. 11:991-99
75. Véniant MM, Sivits G, Helmering J, Komorowski, et al. 2015. Pharmacologic effects of FGF21 are independent of the "browning" of white adipose tissue. Cell Metab. 21:731-38
76. Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, et al. 2013. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat. Med. 19:83-92
77. Lee P, Linderman J, Smith S, Brychta RJ, Perron R, et al. 2013. Fibroblast growth factor 21 (FGF21) and bone: Is there a relationship in humans? Osteoporos. Int. 24:3053-57
78. Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, et al. 2014. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 19:302-9
79. Hondares E, Gallego-Escuredo JM, Flachs P, Frontini A, Cereijo R, et al. 2014. Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue. Metabolism 63:312-17
80. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, et al. 2012. Fibroblast growth factor-21 regulates PPARγactivity and the antidiabetic actions of thiazolidinediones. Cell 148:556-67
81. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, et al. 2013. An FGF21-adiponectinceramide axis controls energy expenditure and insulin action in mice. Cell Metab. 17:790-97
82. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, et al. 2013. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 17:779-89
83. Hsuchou H, Pan W, Kastin AJ. 2007. The fasting polypeptide FGF21 can enter brain from blood. Peptides 28:2382-86
84. Tan BK, Hallschmid M, Adya R, Kern W, Lehnert H, Randeva HS. 2011. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60:2758-62
85. Sarruf DA, Thaler JP, Morton GJ, German J, Fischer JD, et al. 2010. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59:1817-24
86. Owen BM, Bookout AL, Ding X, Lin VY, Atkin SD, et al. 2013. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 19:1153-56
87. Lein ES,Hawrylycz MJ, AoN, Ayres M, Bensinger A, et al. 2007. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445:168-76
88. Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, et al. 2014. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 20:670-77
89. Douris N, Stevanovic D, Fisher FM, Cisu TI, Chee MJ, et al. 2015. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 156:2470-81
90. Johnson CL, Mehmood R, Laing SW, Stepniak CV, Kharitonenkov A, Pin CL. 2014. Silencing of the Fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. Am. J. Physiol. Endocrinol. Metab. 306:E916-28
91. Uonaga T, Toyoda K, Okitsu T, Zhuang X, Yamane S, et al. 2010. FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model. Islets 2:247-51
92. Izumiya Y, Bina HA, Ouchi N, Akasaki Y, Kharitonenkov A,Walsh K. 2008. FGF21 is an Akt-regulated myokine. FEBS Lett. 582:3805-10
93. Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, et al. 2009. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 58:2797-801
94. Kim KH, Kim SH,Min YK, YangHM, Lee JB, LeeMS. 2013. Acute exercise induces FGF21 expression in mice and in healthy humans. PLOS ONE 8:e63517
95. TyynismaaH, Carroll CJ, Raimundo N, Ahola-Erkkila S, Wenz T, et al. 2010. Mitochondrial myopathy induces a starvation-like response. Hum. Mol. Genet. 19:3948-58
96. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, et al. 2013. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 4:2019
97. Yan X, Chen J, Zhang C, Zhou S, Zhang Z, et al. 2015. FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J. Cell. Mol. Med. 19:1557-68
98. Chen WW, Li L, Yang GY, Li K, Qi XY, et al. 2008. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 116:65-68
99. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, et al. 2009. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 58:1532-38
100. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. 2009. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J. Clin. Endocrinol. Metab. 94:3594-601
101. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA,TripathyD. 2009. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32:1542-46
102. Zhang X, Yeung DC, KarpisekM, StejskalD, Zhou ZG, et al. 2008. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-53
103. Li H, Fang Q, Gao F, Fan J, Zhou J, et al. 2010. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J. Hepatol. 53:934-40
104. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, et al. 2010. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur. J. Clin. Investig. 40:887-92
105. Kralisch S, Tonjes A, Krause K, Richter J, Lossner U, et al. 2013. Fibroblast growth factor-21 serum concentrations are associated with metabolic and hepatic markers in humans. J. Endocrinol. 216:135-43
106. Hanks LJ, Casazza K, Ashraf AP, Wallace S, Gutierrez OM. 2015. Fibroblast growth factor-21, body composition, and insulin resistance in pre-pubertal and early pubertal males and females. Clin. Endocrinol. 82:550-56
107. Reinehr T,Woelfle J,Wunsch R, Roth CL. 2012. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J. Clin. Endocrinol. Metab. 97:2143-50
108. Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, et al. 2013. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62:1453-63
109. Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E. 2015. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol. Metab. 4:51-57
110. Davis RL, Liang C, Edema-Hildebrand F, Riley C, Needham M, Sue CM. 2013. Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease. Neurology 81:1819-26
111. Koene S, de Laat P, van Tienoven DH, Vriens D, Brandt AM, et al. 2014. Serum FGF21 levels in adult m.3243A > G carriers: clinical implications. Neurology 83:125-33
112. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, et al. 2013. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18:333-40
113. Kharitonenkov A, Adams AC. 2014. Inventing new medicines: the FGF21 story. Mol. Metab. 3:221-29
114. Gimeno RE, Moller DE. 2014. FGF21-based pharmacotherapy-potential utility for metabolic disorders. Trends Endocrinol. Metab. 25:303-11